The round is the second largest for a biotech startup this year, behind only London-based Verdiva Bio, which creates treatments for obesity and cardiometabolic diseases, which raised $411 million in a Series A in January.
Eikon uses ultra-high-resolution microscopy to study the effects of drugs on living cells. The company is developing treatments for various types of cancer, including breast, ovarian, prostate and melanoma.
According to Crunchbase, the company, founded in 2019, has raised $1.1 billion.
“Eikon has made significant progress in advancing its key stage clinical pipeline and early stage development program, built on our single molecule tracking technology and the deep expertise of our multidisciplinary team,” said Chairman and CEO Dr. Roger Perlmutter. “With clinical trials underway in 28 countries across 5 continents, we are accelerating the development of these much-needed treatments while continuing to expand our R&D capabilities.”
Source: crunchbase
